Serum-Free Cell Culture
Long R3 IGF-1 sustains growth, viability and recombinant-protein productivity of serum-free CHO cell lines, outperforming insulin under production conditions.
≥99% Purity
IGF-1 LR3
IGF-1 analog · serum-free culture supplement
$95.00$47.50/vial with BOGO
USA Lab VerifiedISO/IEC 17025:2017
QuantityBuy 1 Get 1 Free · auto-appliedAdd 2+ items to cart to activate the discount
Free Shipping on orders over $200
PASSEDSterility & Endotoxins
PASSEDNet Content & Purity
Researchers also added
Authenticity
Every vial is QR-authenticated
Scan the QR code on any vial to verify its batch, COA, and origin in seconds. Secure traceability from our lab to your bench.
About this compound
IGF-1 LR3 is a modified version of insulin-like growth factor 1. It is 13 amino acids longer than the natural version and has one amino acid swapped at position 3. That swap keeps it from binding the carrier proteins that normally hold IGF-1 in check, which makes it last much longer. Studies have measured cell growth signaling and protein production in culture.
83-amino-acid IGF-1 analog (70-aa IGF-1 + 13-residue N-terminal extension, Arg3 substitution)
- Formula
- C400H625N111O115S9
- Molecular weight
- 9117.6 g/mol
- Form
- Lyophilized powder
- CAS / ID
- 946870-92-4
0
Amino Acids
70-aa IGF-1 + 13-aa N-terminal extension
0
Molecular Weight (Da)
C400H625N111O115S9
0×
Potency vs Insulin
in serum-free cell culture
0
Research Areas
Serum-Free Cell Culture · More Potent Than Insulin · Myotube Hypertrophy Pathways & more
How It Works
How IGF-1 LR3 works
The pathways IGF-1 LR3 acts on — and what each one does. The animation traces its signal outward from the compound to every target it engages.
Signalling pathways studied in preclinical models · illustrative
Insulin-Like Growth Factor Receptor Activation
IGF-1R Agonism
IGF-1 LR3 (Long R3 IGF-1) is an 83-amino-acid analog of human IGF-1, carrying a 13-residue N-terminal extension and an arginine-for-glutamate substitution at position 3. It binds and activates the type 1 IGF receptor (IGF-1R), a receptor tyrosine kinase, triggering downstream PI3K/Akt and MAPK/ERK signaling.
- Retains near-native affinity for IGF-1R
- Activates PI3K/Akt/mTOR protein-synthesis signaling
- Engages MAPK/ERK proliferation pathways
Extended Bioavailability
Reduced IGFBP Binding
The N-terminal extension and Arg3 substitution lower the analog's affinity for IGF-binding proteins (IGFBPs) by roughly 100- to 1,000-fold relative to native IGF-1. With less of the molecule sequestered by IGFBPs, more remains free to engage IGF-1R, giving a markedly longer functional half-life in culture systems.
- ~100–1,000× lower IGFBP affinity
- Greater free fraction available to the receptor
- Longer-lasting signaling than native IGF-1
Protein Synthesis & Cell Survival
Anabolic Signaling
Through Akt activation, IGF-1 signalling engages mTOR/p70S6K-driven protein synthesis, GSK3β and FoxO-mediated protein degradation — a cascade extensively characterised in skeletal-muscle and cell-culture research models.
- Activates mTOR–p70S6K translation
- Inhibits proteasomal/FoxO degradation
- Anti-apoptotic cell survival measured
Uses & Applications
What IGF-1 LR3 is researched for
The main areas IGF-1 LR3 is being studied for — and the study-reported figures behind them.
Potency vs Insulin in Culture
In serum-free HEK293 culture, LONG R3 IGF-I acts as a more potent growth and survival factor than insulin or native IGF-I, effective at far lower concentrations.
Myotube Hypertrophy Pathways
IGF-1 drives skeletal myotube hypertrophy via PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 signaling — a foundational model for anabolic growth research.
IGF1–Akt/PKB Regulation
The IGF1-Akt/PKB axis controls skeletal-muscle protein synthesis and degradation, as established across transgenic and knockout genetic models.
Molecular Structure
The IGF-1 LR3 molecule
An interactive 3D model rendered from the compound record — rotate and explore its structure.
C400H625N111O115S9
Compound Information
Full specification
| Chemical Name | Long R3 Insulin-Like Growth Factor-1 (IGF-1 LR3) |
| Sequence | 83 amino acids — human IGF-1(1-70) plus 13-residue N-terminal extension; Arg³ |
| Molecular Weight | 9,117.6 Da |
| Molecular Formula | C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉ |
| CAS Number | 946870-92-4 |
| Form | Lyophilized powder |
| Purity | ≥99% (HPLC verified) |
| Testing | Third-party HPLC, Mass Spec, Endotoxin |
| Storage | -20°C for long-term stability |
| Solubility | Sterile acidified water or bacteriostatic water |
| COA | Included with every order |
FAQ
Common questions about IGF-1 LR3
IGF-1 LR3 (Long R3 IGF-1) is an engineered 83-amino-acid analog of human insulin-like growth factor 1. It adds a 13-residue N-terminal peptide extension and replaces the glutamic acid at position 3 with arginine. These changes substantially reduce binding to IGF-binding proteins (IGFBPs) while preserving affinity for the IGF-1 receptor, so it stays active longer than native IGF-1 in culture.
Because it resists IGFBP sequestration and signals potently through IGF-1R, IGF-1 LR3 is a widely used serum-free media supplement. Studies show it supports growth, viability and recombinant-protein productivity of CHO and HEK293 cell lines at concentrations far below those required for insulin.
By activating the IGF-1 receptor tyrosine kinase, it engages the PI3K/Akt/mTOR pathway (protein synthesis and cell survival) and the MAPK/ERK pathway (proliferation). In skeletal-muscle models, the IGF1-Akt axis also suppresses protein degradation via FoxO and GSK3β.
Store the lyophilized powder at -20°C, protected from moisture and light. Avoid repeated freeze–thaw cycles to preserve activity.
No. Research-grade IGF-1 LR3 sold here is strictly for in vitro laboratory research and analytical applications. It is not a drug and is not intended for human or veterinary use, consumption, or any clinical application.
Research Use Only.
Not for human or veterinary use. For in-vitro laboratory research only. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.